Immunotherapies for cancer and infectious diseases
Transgene (Euronext: TNG) is a publicly traded French biotechnology company focused on discovering and developing immune-targeted therapies for the treatment of cancers and infectious diseases.
Transgene (Euronext: TNG) is a publicly traded French biotechnology company focused on discovering and developing immune-targeted therapies for the treatment of cancers and infectious diseases.
Latest News
- May 22, 2019 - Combined General Meeting of May 22, 2019
- May 13, 2019 - Financial visibility extended to Q4 2020, including $10 million revenue from collaboration with AstraZeneca to be received in Q2 2019
- May 13, 2019 - Transgene receives FDA IND Clearance for Lead myvac™ Individualized Immunotherapy, TG4050, to Commence Clinical Development in Ovarian Cancer
- May 9, 2019 - Availability of Preparatory Documents for the Combined General Meeting of May 22, 2019
